ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Bloodspot-based diagnostic test for Fibromyalgia
Wednesday 22 May 2013
Editor's comment: This is the second study in six months to investigate a potential diagnostic blood test for fibromyalgia. The earlier study, published in December, 2012, measured cytokine levels and was able to distinguish FM patients from healthy controls. This study uses spectral and metabolomic analysis and was able to distinguish FM patients from patients with osteoarthritis or rheumatoid arthritis.
A bloodspot-based diagnostic test for fibromyalgia syndrome and related disorders
By Kevin V. Hackshaw, et al.
The aim of this study was to investigate the ability of a rapid biomarker-based method for diagnosis of fibromyalgia syndrome (FM) using mid-infrared microspectroscopy (IRMS) to differentiate patients with FM from those with osteoarthritis (OA) and rheumatoid arthritis (RA), and to identify molecular species associated with the spectral patterns.
Under IRB approval, blood samples were collected from patients diagnosed with FM (n = 14), RA (n = 15), or OA (n = 12). Samples were prepared, placed onto a highly reflective slide, and spectra were collected using IRMS. Spectra were analyzed using multivariate statistical modeling to differentiate groups. Aliquots of samples also were subjected to metabolomic analysis.
IRMS separated subjects into classes based on spectral information with no misclassifications among FM and RA or OA patients. Interclass distances of 15.4 (FM vs. RA), 14.7 (FM vs. OA) and 2.5 (RA vs. OA) among subjects, demonstrating the ability of IRMS to achieve reliable resolution of unique spectral patterns specific to FM.
Metabolomic analysis revealed that RA and OA groups were metabolically similar, whereas biochemical differences were identified in the FM that were quite distinctive from those found in the other two groups. Both IRMS and metabolomic analysis identified changes in tryptophan catabolism pathway that differentiated patients with FM from those with RA or OA.
Source: Analyst, April 17, 2013. By Kevin V. Hackshaw, Luis Rodriguez-Saona, Marçal Plans, Lauren N. Bell and C. A. Tony Buffington. Departments of Internal Medicine, Division of Rheumatology, The Ohio State University, Columbus, OH 43210, USA.
The above originally appeared here.
blog comments powered by Disqus